Cancer News and Research

Latest Cancer News and Research

Raptor and TorreyPines Therapeutics announce merger completion

Raptor Pharmaceuticals Corp. ("Raptor") (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. ("TorreyPines") (Nasdaq: TPTX) announced today the completion of their merger.

1 Oct 2009

Obama's turn to retake lead on health reform nears

President Obama's turn to step to the lead regarding the shape of health reform legislation is quickly approaching.

1 Oct 2009

Vertex Pharmaceuticals to receive $155 million in cash from two financial transactions

Vertex Pharmaceuticals Incorporated today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes repayable no later than October 31, 2012 in the total amount of $155 million.

1 Oct 2009

Ardea's to present its hyperuricemia canditate study results at the ACR/ARHP Scientific Meeting

Ardea Biosciences, Inc. announced that it will present results from a Phase 2a, proof-of-concept study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, at the 2009 American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting in Philadelphia, Pennsylvania.

1 Oct 2009

Parabon Nanolabs receives SBIR grant to design DNA biometric devices

Parabon NanoLabs (PNL), a leading designer and manufacturer of breakthrough, nano-enabled products, announced today its award of a Department of Homeland Security (DHS) Small Business Innovative Research (SBIR) grant.

1 Oct 2009

PSA test vital for assessing prostate cancer

When it comes to the prostate cancer, the disease known as the "silent killer" because it often exhibits no symptoms, to be forewarned is to be forearmed. It is the second leading cancer killer in men, just behind lung cancer. Every year, more than 218,000 men are diagnosed with prostate cancer in the United States, claiming about 28,000 lives.

1 Oct 2009

Update from BioCryst Pharmaceuticals regarding intravenous peramivir

BioCryst Pharmaceuticals, Inc. today announced that it has delivered a written response to the request for proposal (RFP) announced on September 21, 2009 from the U.S. Department of Health & Human Services (HHS) for the supply of intravenous (i.v) peramivir for the treatment of critically ill influenza patients under Emergency Use Authorization (EUA). BioCryst management intends to provide an update once the RFP process has reached a conclusion.

1 Oct 2009

Welichem announces filing of clinical trial application with Health Canada

Welichem Biotech Inc. (the "Company") announces the filing with Health Canada of a clinical trial application for its lead, anti-inflammatory drug WBI-1001. The application is for a 3-month, double blinded clinical trial in patients with chronic atopic dermatitis at three trial centres.

1 Oct 2009

Scientists report new development for diagnosing malignant melanoma

Scientists in Australia are reporting development and testing in laboratory animals of a potential new material for diagnosing malignant melanoma, the most serious form of skin cancer. Their study is scheduled for the September 10 issue of the ACS' Journal of the Medicinal Chemistry, a bi-weekly publication.

1 Oct 2009

Respiragene test for lung cancer motivates smokers to quit smoking

Smokers who learn their personal risk of lung cancer through gene-based risk assessment are more likely to be motivated to quit their habit, according to Dr. W. Jeffrey Allard, clinical affairs director of Synergenz Bioscience Ltd.

1 Oct 2009

National Institutes of Health awards $16.8 million grant to Hutchinson Center/UW group

The National Heart, Lung and Blood Institute of the National Institutes of Health has awarded a $16.8 million, seven-year grant to launch a bicoastal research partnership between Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium and Children's Hospital of Philadelphia.

30 Sep 2009

Prism 3.0 Electronic Data Capture solution launched by Nextrials

Nextrials, Inc. (www.nextrials.com), a leader in clinical research software and services, today announced a significant upgrade for its flagship electronic data capture and clinical trial management platform, Prism™.

30 Sep 2009

Immunocellular Therapeutics' pilot study can help in early cancer detection

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today results from its pilot study evaluating the cancer detection abilities of one of its lead monoclonal antibody product candidates, ICT-109. Data from this study demonstrated that ICT-109 had a statistically significant ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets.

30 Sep 2009

Lumenis to discuss different treatment options for laryngeal cancer at 2009 AAO-HNS

Lumenis Ltd., the world's largest medical laser company, announced today they will be focusing their attention at this year's AAO-HNS annual meeting in San Diego, California, on an educational event to discuss different treatment options for laryngeal cancer.

From Lumenis Inc. 30 Sep 2009

SBIR grant from NIH to GenVec for metastatic cancer research

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.

30 Sep 2009

Research study on teens who underwent laparoscopic bypass surgery

According to a recent study of clinical characteristics of teens who underwent laparoscopic Roux-en-Y gastric bypass surgery from 2002 until 2007, doctors may have a much narrower window of opportunity to reverse morbid obesity in teens than previously thought.

30 Sep 2009

Orphan drug designation for pixantrone applied by Cell Therapeutics

Cell Therapeutics, Inc. ("CTI") announced today that it has applied to the European Medicines Agency (EMEA) for orphan drug designation for pixantrone. CTI initiated the process of obtaining marketing approval in Europe in July, 2009, for the treatment of relapsed or refractory aggressive NHL.

30 Sep 2009

Hologic's ThinPrep integrated imager receives CE marking approval

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced it has received CE marking approval for its ThinPrep® integrated imager.

From Hologic, Inc. 30 Sep 2009

New center for gastrointestinal cancer research established

Georgetown University Medical Center today announced the creation of a center that may help advance a cure for one of the deadliest forms of cancer. The Otto J. Ruesch Center for the Cure of Gastrointestinal (GI) Cancers will fund gastrointestinal cancer research, drug discovery and patient advocacy efforts at the Georgetown Lombardi Comprehensive Cancer Center.

30 Sep 2009

ARRA stimulus funds fuel research projects across America

The Association of American Universities (AAU), the Association of Public and Land-grant Universities (APLU), and The Science Coalition (TSC) today released highlighted examples of the important scientific work happening across the country as a result of the American Recovery and Reinvestment Act of 2009 (ARRA). The brief report summarizes just a handful of the thousands of projects benefiting from stimulus dollars.

30 Sep 2009